{
    "doi": "https://doi.org/10.1182/blood-2020-141213",
    "article_title": "Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry ",
    "article_date": "November 5, 2020",
    "session_type": "615.Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation",
    "abstract_text": "Background: Options to treat elderly patients with newly diagnosed AML include intensive, attenuated chemotherapy, hypomethylating agents (HMA) and supportive care (SC). HMA have proven their efficacy in DACO-016 (NCT00260832) and AML-001 (NCT01074047) clinical trials, with a median overall survival (OS) of 7.7 months (95%CI, 6.2 to 9.2) with decitabine (DEC) vs. 5.0 months (95%CI, 4.3 to 6.3) with therapy choice (TC), considered SC or low-dose Ara-C (LDAC). Median OS was 10.4 months with azacitidine (AZA) (95%CI, 8.0 to 12.7) vs. 6.5 months (95%CI, 5.0 to 8.6) with conventional care regimens (CCR), considered standard induction chemotherapy, LDAC or SC. However, there are few direct comparative data of AZA and DEC in the context of trials or real-life settings. Aims: Here, we compared clinical outcomes between AZA and DEC in AML patients not eligible for intensive chemotherapy in the epidemiologic PETHEMA registry. Methods: We included newly diagnosed AML patients treated with AZA (75 mg/m2/d IV or SC days 1-7) or DEC (20 mg/m2/d IV days 1-5) that were not eligible for intensive chemotherapy. Responses were recorded using IWG 2003 criteria. Rates of Complete Response (CR), complete response with incomplete recovery (CRi) and OS were co-primary endpoints. Results: Between 2006 and 2019, 638 patients were included. 497 (78%) received AZA and 141 (22%) received DEC as per physician judgement. Baseline characteristics were comparable in both groups (Table 1), except for bone marrow blasts count \u2265 30%, which was more frequent in DEC group (59.2% vs 77.1%, p<0.001). The CR rate was 16.3% vs 20.6% (p = 0.23); composite CR (CR+CRi) was 18.5% vs 22% (p = 0.35), and the overall response rate (ORR, partial remission (PR) plus CR+CRi) was 29.2% vs 34.8% (p=0.20); for AZA vs DEC, respectively. A significantly higher ORR to AZA was associated with ECOG <2 (33.9% vs. 12.4% in patients with ECOG \u22652, OR 0.22, 95% CI 0.10 - 0.49, p=0.000), de novo AML (35.3% vs. 21.9% in secondary AML; OR 0.38, 95% CI 0.20 - 0.71, p=0.002) and estimated glomerular filtrate rate \u2265 45 mL/min/1.73m 2 (30.4% vs. 9.3% in patients with estimated glomerular filtrate rate \u2265 45 mL/min/1.73m 2 ; OR 0.15, 95% CI 0.034 - 0.67, p=0.013); while bone marrow blast count < 50% was the only factor influencing ORR to DEC (43.7% vs. 25% in \u2265 50% bone marrow blasts, p=0.029). With a median follow up of 12 months, median OS was 10.0 (95% CI 8.7 - 11.2) vs 8.0 (5.7- 10.2) months for AZA vs DEC, respectively (p = 0.46) (Figure 1). Median OS was 21 (17.8 - 24.1) vs 16 (12.6 - 19.3) vs 6 months (5.0 - 7.0) for patients who achieved CR/CRi vs PR vs no response (p<0.001) (Figure 2). Additional subgroup analyses by baseline characteristics performed to compare AZA vs DEC revealed that patients \u2265 80 years did benefit for treatment with AZA, median OS of 8 vs. 4 m (p=0.042), as well as patients with WBC \u2265 10 x10 9 /L (8 vs. 5 m, p=0.036), platelet count <20 x10 9 /L (8 vs. 4 m, p=0.021) and those with estimated glomerular filtrate rate \u2265 45 mL/min/1.73m 2 (10 vs. 5m, p=0.033). Conclusions: This is a large retrospective comparison with long-term follow-up of clinical outcomes associated with AZA and DEC treatment for patients with AML patients not eligible for intensive chemotherapy. There were no significant differences in ORR, CR/CRi or OS between AZA and DEC. However, patients with WBC \u2265 10 x10 9 /L, platelet count <20 x10 9 /L and estimated glomerular filtrate rate \u2265 45 mL/min/1.73m 2 could benefit from AZA in terms of OS. View large Download slide View large Download slide  Close modal Disclosures Tormo: Janssen: Honoraria; Daiichi Sankyo: Honoraria; Servier: Honoraria; Roche: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Honoraria. Ramos: Amgen: Consultancy, Other: travel grant ; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel grant , Research Funding; Novartis: Consultancy, Other: travel grant; Takeda: Consultancy, Other: travel grant ; Daiichi-Sankyo: Other: travel grant ; Merck-Sahrp & Dohme: Other: travel grant; Rovi: Other: travel grant; Roche: Other: travel grant ; Jannsen: Other: travel grant; Abbvie: Consultancy, Other: travel grant .",
    "author_names": [
        "Jorge Labrador",
        "David Mart\u00ednez-Cuadr\u00f3n, MD",
        "Adolfo de la Fuente",
        "Rebeca Rodr\u00edguez-Veiga, MD",
        "Josefina Serrano, MD",
        "Mar Tormo, MD",
        "Jose Antonio P\u00e9rez-Sim\u00f3n, MD",
        "Fernando Ramos",
        "Teresa Bernal del Castillo, MD PhD",
        "Maria L\u00f3pez-Pav\u00eda",
        "Fernanda Trigo",
        "Pilar Martinez Sanchez",
        "Juan Ignacio Rodriguez-Gutierrez",
        "Carlos Rodriguez",
        "Cristina Gil",
        "Daniel Garcia",
        "Susana Vives, MD",
        "Maria Angeles Foncillas",
        "Manuel Perez Encinas, MD",
        "Andr\u00e9s Novo, MD",
        "Isabel Recio",
        "Gabriela Rodriguez-Mac\u00edas, MD",
        "Juan Miguel Bergua Burgues, MD",
        "Victor Noriega Concepcion",
        "Esperanza Lavilla",
        "Alicia Rold\u00e1n P\u00e9rez",
        "Miguel A. Sanz, MD",
        "Pau Montesinos, MD PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Jorge Labrador",
            "author_affiliations": [
                "Hematology Department, Research Unit, Hospital Universitario de Burgos, Burgos, Spain "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "David Mart\u00ednez-Cuadr\u00f3n, MD",
            "author_affiliations": [
                "CIBERONC Instituto de Salud Carlos III, Madrid, Spain ",
                "Hematology and hemotherapy department, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Adolfo de la Fuente",
            "author_affiliations": [
                "MD Anderson Cancer Center, Madrid, Spain "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rebeca Rodr\u00edguez-Veiga, MD",
            "author_affiliations": [
                "CIBERONC Instituto de Salud Carlos III, Madrid, Spain ",
                "Hospital Universitari i Polit\u00e9cnic La Fe, Valencia, Spain "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Josefina Serrano, MD",
            "author_affiliations": [
                "Clinical Hematology, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar Tormo, MD",
            "author_affiliations": [
                "Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose Antonio P\u00e9rez-Sim\u00f3n, MD",
            "author_affiliations": [
                "Department of Hematology, Hospital Universitario Virgen del Rocio; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla,Spain, Sevilla, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fernando Ramos",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario de Le\u00f3n, Le\u00f3n, Spain, Le\u00f3n, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Bernal del Castillo, MD PhD",
            "author_affiliations": [
                "Hospital Universitario Central Asturias, ISPA, IUOPA, Oviedo, Spain "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria L\u00f3pez-Pav\u00eda",
            "author_affiliations": [
                "Hospital General Universitari de Val\u00e8ncia, Hematology Service, Valencia, Spain "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fernanda Trigo",
            "author_affiliations": [
                "Dept. of Clinical Hematology, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, Porto, Portugal "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Martinez Sanchez",
            "author_affiliations": [
                "Clinical Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Ignacio Rodriguez-Gutierrez",
            "author_affiliations": [
                "Hospital Universitario Basurto, Bilbao, Spain "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Rodriguez",
            "author_affiliations": [
                "Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas de Gran Canaria, Spain "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Gil",
            "author_affiliations": [
                "Hematology Department, Hospital General Universitario de Alicante, Alicante, Spain "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniel Garcia",
            "author_affiliations": [
                "Hematology Department, Hospital Sanitas La Zarzuela, Madrid, Spain "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Susana Vives, MD",
            "author_affiliations": [
                "Hematology Department, ICO - Hospital Germans Trias i Pujol, Badalona, Spain "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Angeles Foncillas",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Manuel Perez Encinas, MD",
            "author_affiliations": [
                "Hospital Cl\u00ednico Universitario de Santiago de Compostela, Santiago de Compostela, Spain "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andr\u00e9s Novo, MD",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Isabel Recio",
            "author_affiliations": [
                "Hematology Deparment, Complejo Asistencial de \u00c1vila, Avila, Spain "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gabriela Rodriguez-Mac\u00edas, MD",
            "author_affiliations": [
                "Hematology and hemotherapy department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Miguel Bergua Burgues, MD",
            "author_affiliations": [
                "Hematology and hemotherapy department, Hospital San Pedro de Alc\u00e1ntara, C\u00e1ceres, Spain "
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Victor Noriega Concepcion",
            "author_affiliations": [
                "Hospital Universitario de A Coru\u00f1a, A Coru\u00f1A, ESP "
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Esperanza Lavilla",
            "author_affiliations": [
                "Hospital Universitario Lucus Augusti, Lugo, Spain "
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alicia Rold\u00e1n P\u00e9rez",
            "author_affiliations": [
                "Hematology and hemotherapy department, Hospital Universitario Infanta Sof\u00eda, San Sebasti\u00e1n de los Reyes, Spain "
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel A. Sanz, MD",
            "author_affiliations": [
                "CIBERONC Instituto de Salud Carlos III, Madrid, Spain ",
                "Hematology and hemotherapy department, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain ",
                "Programa Espa\u00f1ol de Tratamientos en Hematologia, PETHEMA, Valencia, Spain "
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pau Montesinos, MD PhD",
            "author_affiliations": [
                "Programa Espa\u00f1ol de Tratamientos en Hematologia, PETHEMA, Valencia, Spain ",
                "CIBERONC, Instituto de Salud Carlos III, Madrid, Spain ",
                "Hematology Department, Hospital Universitario La Fe de Valencia,, Valencia, Spain"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-20T02:33:36",
    "is_scraped": "1"
}